Results 61 to 70 of about 47,712 (207)

Some doubts about the mantra on the deleterious cardiovascular effects of sulfonylureas [PDF]

, 2017
[No abstract ...
Prudente, Sabrina, Trischitta, Vincenzo
core   +1 more source

Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis

Journal of Diabetes Research, 2019
Background. Glucagon-like peptide-1 (GLP-1) receptor agonists are effective glucose-lowering drugs, but there is concern that they may increase the risk of malignant neoplasia. The present meta-analysis examined the safety of GLP-1 receptor agonists with
Yufang Liu, Xiaomei Zhang, Sanbao Chai, Xin Zhao, Linong Ji   +4 more
doaj   +1 more source

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes [PDF]

, 2016
Background The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. Methods In this double-blind trial, we randomly assigned patients with type 2 diabetes
Bergenstal, RM, Brown-Frandsen, K, Buse, JB, Daniels, GH, Kristensen, P, LEADER Steering Committee on behalf of the LEADER Trial Investigators, Mann, JF, Marso, SP, Nauck, MA, Nissen, SE, Pocock, S, Poulter, NR, Ravn, LS, Steinberg, WM, Stockner, M, Zinman, B   +15 more
core   +1 more source

Glucagon-like peptide-1 receptor agonists and derivatives in the treatment of obesity - review

Quality in Sport
: Obesity is a chronic and insidious disease that represents a significant global. The World Health Organization has announced that almost 60% of European adults are overweight or obese.
Michal Rabenda, Adam Słomczyński, Piotr Zatyka, Agata Pawłowska, Dominika Opala, Dobromiła Osuch, Piotr Janik   +6 more
doaj   +1 more source

Type 2 Diabetes Mellitus and Glucagon Like Peptide-1 Receptor Signalling [PDF]

, 2013
It has been estimated that approximately 8.4% of the world population currently live with diabetes mellitus and type 2 diabetes is the most common form. Type 2 diabetes increases the risk of complications such as heart attacks, blindness, amputations and
Venkat Kanamarlapudi
core   +1 more source

Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection Versus Insulin Alone in Type 2 Diabetes [PDF]

, 2018
Context Glucagon-like peptide-1 (GLP-1) and the clinically available GLP-1 agonists have been shown to exert effects on the heart. It is unclear whether these effects occur at clinically used doses in vivo in humans, possibly contributing to CVD risk ...
Considine, Robert V., Goodwill, Adam, Green, Mark A., Hamilton, LaTonya, Hutchins, Gary D., Mather, Kieren J., Mathias, Carla, Patel, Niral A., Territo, Wendy, Tune, Johnathan D.   +9 more
core   +1 more source

Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. [PDF]

, 2017
Importance: Glucagon-like peptide-1 (GLP-1) receptor agonists are effective therapies for the treatment of type 2 diabetes and are all currently available as an injection.
Davies, Melanie, Hansen, Oluf K.H., Hartoft-Nielsen, Marie-Louise, Jabbour, Serge, Pieber, Thomas R., Rosenstock, Julio   +5 more
core   +1 more source

GLP-1 Receptor Agonist

The Journal of Korean Diabetes
Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by food intake from L cells of the ileum. GLP-1 contributes to blood glucose control through three main mechanisms: promoting glucose-dependent insulin secretion from pancreatic beta cells, suppressing glucagon hypersecretion from pancreatic alpha cells, and delaying gastric emptying time.
openaire   +1 more source

A meta-analysis of the incidence of acne vulgaris in patients treated with GLP-1 agonists

International Journal of Women's Dermatology
Background:. With the emerging popularity of GLP-1 receptor agonists, patients are noticing acne vulgaris side effects that are seemingly related to the concurrent treatment with the drug.
Oluwafunke O. Ogunremi, BS, Sana F. Ismail, BS, Ramneek K. Dhami, BS, Jazmin S. Newton, MD, Scott A. Kindle, MD, Valeriy Kozmenko, MD   +5 more
doaj   +1 more source

Cyclic AMP signalling in pancreatic islets [PDF]

, 2010
Cyclic 3'5'AMP (cAMP) is an important physiological amplifier of glucose-induced insulin secretion by the pancreatic islet β-cell, where it is formed by the activity of adenylyl cyclases, which are stimulated by glucose, through elevation in ...
Furman, Brian, Ong, Wee Kiat, Pyne, Nigel J.   +2 more
core   +1 more source